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Background: The best data on prognosis comes from population-based incident cohorts but few such
cohorts exist for Parkinson's disease and atypical parkinsonism.
Methods: The PINE study is a prospective follow-up study of an incident cohort of people with degen-
erative or vascular parkinsonism and age-sex matched controls. Participants have annual follow-up from
diagnosis until death with review of primary/secondary care records and linkage to the UK death register.
Data are collected on survival, disability (dependency on others for activities of daily living) and insti-
tutionalization. Research criteria are used to guide the clinical diagnosis, which is updated annually. We
compared all-cause mortality, disability and institutionalization in patients (subdivided by diagnosis)
and controls, adjusted for important confounders.
Results: 323 incident parkinsonian patients (199 Parkinson's disease, 124 atypical parkinsonism, mean
age at diagnosis 75yrs) and 262 controls (mean age 75yrs) had 1349 and 1334 person-years follow-up
respectively (maximum follow-up 10 years). All outcomes were worse in parkinsonian patients than
controls, especially in atypical parkinsonism (adjusted mortality hazards ratios Parkinson's disease 2.49,
95%CI 1.72e3.58, atypical parkinsonism, 6.85, 95%CI 4.78e9.81). Median survival times for Parkinson's
disease and atypical parkinsonism were 7.8 and 2.7 years respectively but were very age-dependent. At
three years the rates of death or dependency were controls 21%, Parkinson's disease 46%, atypical
parkinsonism 96% whilst overall institutionalization rates were 5%, 15% and 55% respectively.
Conclusion: The prognosis of Parkinson's disease and atypical parkinsonism in this unselected incident
cohort was signiﬁcantly worse than previously reported. This has important implications for patient
management.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prognosis is a fundamental aspect in understanding any disease.
Only with a clear knowledge of prognosis, and factors that inﬂu-
ence it, can clinicians give patients appropriate information and
plan management, whilst healthcare providers and researchers
need this information to develop appropriate services and plan
new trials [1]. For neurodegenerative diseases like Parkinson's
disease (PD), prognostic studies should assess all important aspects
of prognosis including survival, disease progression in terms of
impairment, disability and quality of life, the development of motor
and non-motor complications and the risk of long-term care in a
nursing/residential home, a major driver of overall costs of care [2].nsell).
Ltd. This is an open access article uThe optimal design for a prognostic study is prospective follow-
up of a representative group of patients from diagnosis to death,
ideally an incident cohort of patients [3]. Unfortunately, to our
knowledge, only one true incidence study of PD or any other
parkinsonian disorder has provided long-term prognostic data [4],
although a few population-based studies using inception cohorts
from the time of diagnosis have published survival data [5]. Hence,
it is not surprising that there is still substantial uncertainty about
important aspects of PD prognosis, including the degree to which
mortality is increased: studies have found the relative risk of
mortality in PD varies between 0.95 and 3.79 and median survival
ranges from six to 22 years [5].
The Parkinsonism Incidence in North-East Scotland (PINE) study
prospectively identiﬁed and followed up a population-based inci-
dent cohort of PD and other degenerative or presumed vascular
parkinsonian conditions along with an age-sex matched
community-based control group. The incidence results have beennder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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prognosis of the patients (subdivided by diagnosis) versus con-
trols with respect to survival, disability (dependency on others for
activities of daily living), and institutionalization.
2. Methods
The PINE study recruited all patients with a newly diagnosed
presumed degenerative or vascular parkinsonian syndrome over
4.5 years from a baseline population of about 315,000 registered
with 37 primary care practices in and around Aberdeen, Scotland
(pilot study 2002-04, main study 2006-09) [6]. Multiple over-
lapping searches were used to minimize the risk of missing pa-
tients, including direct referral from all primary and secondary care
physicians serving this population who were sent regular re-
minders, hand-searching of secondary care referrals, regular elec-
tronic searches of primary and secondary care databases and
limited screening of the population over 65 years old. Parkinsonism
was deﬁned as two or more cardinal motor signs (bradykinesia,
rigidity, rest tremor, otherwise unexplained postural instability).
Patients with drug-induced parkinsonism (resolvedwithin six to 12
months of stopping the responsible drug or, if the drug could not be
stopped, when 123I ioﬂupane (FP-CIT) single photon emission
computed tomography was normal) were excluded. Eligible pa-
tients and their carers were offered ongoing life-long yearly follow-
up with linkage to the national death register. Clinical care was not
altered by participation in the study.
At each annual review the parkinsonian syndrome was classi-
ﬁed by a single consultant neurologist with movement disorders
expertise (CEC) using all available information (clinical syndrome,
atypical features, response to dopamine replacement therapy,
development of motor complications, results of structural (CT or
MRI) or FP-CIT brain scans where undertaken on the basis of clinical
need), by applying the appropriate research criteria available at the
time for PD [7], dementia with Lewy bodies (DLB) [8], multiple
system atrophy (MSA) [9], progressive supranuclear palsy (PSP)
[10], corticobasal degeneration (CBD) [11] and vascular parkin-
sonism [12]. If patients fulﬁlled criteria for more than one condi-
tion, the diagnosis that ﬁtted best was assigned. In those who died
the ﬁnal diagnosis was made after reviewing all the clinical and
imaging information held in their research ﬁles and the annual
videotaped examinations or from pathology in those who had
given consent for post-mortems.
For each eligible patient who consented to follow-up we tried to
identify an age-sex matched control from the same primary care
practice or a register of elderly people who had taken part in a
previous community-based screening project [13]. We have pre-
viously shown that the controls had similar health indices to the
general population and those who consented were not signiﬁcantly
healthier than those who did not [13]. For some patients we failed
to recruit a control.
2.1. Assessments/outcome measures
Patients and controls who gave consent had a standardized
baseline visit at diagnosis and annually thereafter including clinical
examination looking for features of an atypical parkinsonian syn-
drome and assessment of: (i) parkinsonian impairment (UPDRS
part III motor score, hand tapping test); (ii) mobility (timed 6m get-
up-and-go walk); (iii) disease stage (Hoehn-Yahr), (iv) disability
(Schwab & England [S&E], Barthel index); (v) quality of life (Par-
kinson's Disease Questionnaire 39 item [PDQ-39], Euroquol-5D
[EQ-5D]); (vi) motor complications (UPDRS part IV); (vii) cognitive
function (mini-mental state examination (MMSE), mini-mental
Parkinson's [MMP]); (viii) mood (Geriatric Depression Scale 15item version [GDS-15]); (ix) other non-motor complications
including falls and fractures, pain, autonomic and sleep problems
using a symptom checklist. The measurement scales were selected
on the basis of clinical relevance, validity and reliability. Some pa-
tients only consented to limited assessment including UPDRS mo-
tor score, S&E score, MMSE and the checklist of motor and non-
motor complications. Those who were unable to come to clinic
were visited in the community in their home/institution.
Each year we also updated information about other medical
conditions and their medication by reviewing each participant's
hospital and primary care record. We also collected information
about place of residence for data on institutionalization (admission
to a nursing or residential care home) and for those who died we
collected details about the date, place and cause of death from
death certiﬁcates and primary and secondary care records.
Parkinsonism-related deaths were deﬁned as those due to end-
stage parkinsonism or due to complications of parkinsonism such
as immobility, aspiration pneumonia, or falls.
2.2. Analysis
Outcome data were extracted on 31st March 2013 when all
participants had at least three years follow-up. Baseline charac-
teristics were described using frequency/percentage for categorical
variables, mean/standard deviation for continuous variables with a
normal distribution and median/interquartile range if skewed.
Time-to-death from date of diagnosis censored at last known
follow-up date was plotted with a Kaplan-Meier curve and
compared between three diagnostic groups (control, PD, atypical
parkinsonism which combined the diagnoses other than PD) using
Cox regression. Adjusted hazard ratios (HRs) and 95% CIs were
calculated with ﬁxed entry of a pre-deﬁned set of potential con-
founders measured at the baseline/diagnostic assessment, which
were selected on the basis of clinical plausibility and previous
literature reviews. These were age, sex, living alone [yes/no], so-
cioeconomic deprivation category based on the Carstairs index
from the 2001 Scottish census (1¼most afﬂuent, 6¼ least afﬂuent)
[14], vascular co-morbidity [any previous symptomatic stroke/
transient ischaemic attack/ischaemic heart disease/peripheral
vascular disease or diabetes], and smoking status [ever versus
never]). Time-to-institutionalization for those not institutionalized
at baseline was assessed between diagnostic groups using a
competing risk model to account for the competing risk of death
prior to institutionalization with adjustment for same confounder
variables as for death. The Fine-Gray approach was used to model
the cumulative incidence function, which was plotted rather than a
standard Kaplan-Meier plot because of the competing risk for
death.
Signiﬁcant disability was deﬁned as S&E score <80, which was
deﬁned in PINE as being dependent on others for basic activities of
daily living (washing, dressing, toileting, feeding, walking). Dead or
dependent (deﬁned as dead or S&E < 80) at three years follow-up
was analysed using logistic regression with adjustment as per the
time-to-event models.
The overall sample size was deﬁned by the cohort sizes. The
survival model was ﬁtted on those with complete confounder in-
formation (n ¼ 573); the time-to-institutionalization model was
ﬁtted on those with complete confounder information who were
not institutionalized at baseline (n¼ 545) and the logistic model for
death or dependency at three years was ﬁtted on all those with
Schwab and England scores at three years who were independent
at baseline (n ¼ 393). No imputation of missing data was per-
formed. Analysis was carried out using SAS v9.3 with the
competing risk analysis undertaken in STATA 13.
The study was approved by the NHS Grampian Research Ethics
S. Fielding et al. / Parkinsonism and Related Disorders 32 (2016) 36e4138Committee and the Multicentre Research Ethics Committee A for
Scotland, which gave agreement to include patients with dementia
who lacked capacity to consent with a guardian's assent.
3. Results
3.1. Patient characteristics
Of 377 patients with suspected incident parkinsonism, 355 pa-
tients (94%) gave consent for follow-up who were subdivided into
six diagnostic groups: PD (n ¼ 199), DLB (n ¼ 43) [one person with
parkinsonism associated with Alzheimer's was included in this
group rather than excluded], MSA (n ¼ 16), PSP (n ¼ 24) combined
with CBD (n ¼ 3), vascular parkinsonism (n ¼ 38) and non-eligible
(n ¼ 32), where it became clear with follow-up that either they
were not parkinsonian (such as those with essential or dystonic
tremors) or probably had drug-induced parkinsonism. The latter
were excluded, leaving 323 parkinsonian patients for analysis. Of
614 controls approached, 266 (43%) were recruited, of whom 262
were included in analysis as four became parkinsonian during
follow-up. There were very few losses after 1349 and 1334 person-
years of follow-up in patients and controls respectively (follow-up
range 0.5e10.1 years) [Table 1, supplementary Fig. e1].
Table 1 shows the baseline characteristics of the participants.
The cohort was overwhelmingly Caucasian, reﬂecting the demog-
raphy of the study area, and elderly. Patients were seen and diag-
nosed relatively soon after the onset of their symptoms (median
delay 15months) but despite this manywere dependent at baseline
(for example, 26% of PD at baseline). As expected, atypical parkin-
sonian disorders had more severe physical and cognitive impair-
ments at baseline than PD with less tremor and more postural
instability/falls. Thirty of the 169 (18%) patients who died had brain
autopsies to conﬁrm the diagnosis.
Ninety-two percent of PD patients (184/199) were treated with
dopamine replacement therapy during follow-up (11% dopamine
agonist monotherapy, 89% levodopa monotherapy/combination
therapy). The remaining 15 patients either died before treatment
was indicated or decided to remain off treatment up to the latest
follow-up. Mean levodopa equivalent daily doses (LEDD) at one,
three and ﬁve years of follow-up were 353 mg, 429 mg and 502 mg
respectively. Sixty-one percent of the atypical parkinsonian pa-
tients (76/124) had a trial of treatment (levodopa in all except one)
and 34 were still on treatment at three years (mean LEDD 428 mg).
3.2. All-cause mortality
Median survival was 7.8 years for the PD cohort and 2.7e3.3
years for the other parkinsonian syndromes (Table 1, Fig. 1). How-
ever, themedian survival in PDwas heavily inﬂuenced by age, being
inestimable in those aged under 70 at diagnosis because 50% had
not died during follow-up and about 4 years in those aged 80 or
more (supplementary Fig. e2). Fifty-seven percent (97/169) of
deaths were directly or indirectly related to parkinsonism, signiﬁ-
cantly higher (p < 0.0001, Chi-squared test) in the atypical syn-
dromes (71%) than PD (40%). Kaplan-Meier survival curves by
speciﬁc diagnostic group showed no difference in mortality (log
rank test p ¼ 0.998) between the DLB, Parkinson's plus (PSP/CBD or
MSA) and vascular groups (supplementary Fig. e3) and so these
were combined into one atypical parkinsonism group for subse-
quent analyses to improve power because of the small number of
people in these diagnostic groups (Fig. 1, supplementary Table e1).
In the Cox regression models, people with PD (HR 2.49, 95% CI
1.72e3.58) and atypical parkinsonism (HR 6.85, 95% CI 4.78e9.81)
had signiﬁcantly worse survival than controls (Table 2) and those
with atypical parkinsonism hadworse survival compared to PD (HR3.02, 95% CI 2.15e4.24). Age, vascular co-morbidity and socioeco-
nomic category were independently associated with mortality
(supplementary Table e2).
4. Institutionalization
There were high rates of institutionalization (Fig. 2, supple-
mentary Table e1), especially in the DLB group where the median
time-to-institutionalization was 1.8 years (Table 1, supplementary
Fig. e4). The rates for PD varied by age (supplementary Table e3).
People with atypical parkinsonism and PD were respectively nearly
14 and four fold more likely to be institutionalized than controls in
the competing risk analyses (Table 2), whilst those with atypical
parkinsonism were about four times more likely to be institution-
alized than PD (HR 3.78, 95% CI 2.25e6.34).
4.1. Dead or dependent at three years
Nearly all patients with atypical parkinsonian syndromes and
50% of those with PD were dead or required help from others in
basic activities of daily living by three years compared to about 20%
of controls. The rates for controls and PD were age-dependent
(supplementary Table e3). In those independent at baseline
(n ¼ 393) there was an increased odds of death or dependency of
about four-fold for PD (odds ratio [OR] 3.87 95%CI 2.18e6.86) and
45-fold (OR 45.3 95%CI 15.3e134.5) for atypical parkinsonism
(Table 2, supplementary Table e2) compared to controls, whilst the
ORwas 3.02 (95% CI 2.15e4.24) for atypical parkinsonism relative to
PD.
5. Discussion
This prospective incident cohort study found that mortality,
institutionalization and dependency rates were signiﬁcantly higher
in PD and especially in atypical parkinsonian syndromes compared
to controls. The median survival times of the atypical syndromes
were comparable to motor neuron disease [15]. Institutionalization
was especially common for those with DLB and nearly all of those
with atypical syndromes and 50% of those with PD were dead or
dependent three years from diagnosis.
The HR for mortality in PD in this study (2.49) was higher than
the standardized mortality ratios (range 1.1e2.9) and HRs
(1.76e2.32) found in most previous cohorts studied from diagnosis
[5] and our median survival of 7.8 years was shorter than previous
studies [5]. However, most of these studies were not cohorts based
on all incident patients identiﬁed from a population over a given
time-period. Therefore, they may have suffered from selection bias
such that thosewith poorer outcomes (e.g. the elderly) were under-
represented. It is also possible that our control group was healthier
than the general population, which would have inﬂated the HR
although a previous analysis had not supported this [13]. The only
previous data from an incident PD cohort [4] also found a lower
mortality ratio than our study (1.29) and longer median survival
(10.3 years), which may be partly explained by a lower mean age at
diagnosis (70 years) and longer follow-up (mean 7.2 years).
Our data on the rate for death and dependency in PD are novel
since there are no data from incident cohorts. The 3-year rate was
much higher than expected: a previous hospital-based inception
cohort found only 16% of patients had disability/dependency at
three years [16], but this study included younger patients (mean
age at diagnosis 65 years) and had a lower S&E cut-off for de-
pendency (70) thanwe used. Only one small (n ¼ 89) incident PD
cohort has reported data on institutionalization and found a higher
relative risk (6.7) than we did but the 95% conﬁdence interval was
wide (3.7e12.1) and overlapped with ours [17].
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Parkinson plus syndromes Atypical Parkinsonism
combined (n ¼ 124)
PSP/CBD (n ¼ 27) MSA (n ¼ 16)
Baseline characteristics
Male 162 (62%) 115 (58%) 27 (71%) 29 (67%) 13 (67%) 12 (75%) 81 (65%)
Mean age yrs (SD) 74.9 (9.3) 71.9 (10.4) 78.5 (7.4) 79.0 (6.2) 78.5 (8.5) 78.3 (9.3) 78.6 (7.4)
Caucasian 251 (96%) 198 (99%) 38 (100%) 43 (100%) 27 (100%) 16 (100%) 124 (100%)
Living Alone a 86 (33%) 53 (27%) 15 (39%) 13 (30%) 6 (22%) 5 (31%) 39 (31%)
Carstairs deprivation categoryz
1e2 (most afﬂuent) 120 (46%) 104 (52%) 15 (37%) 29 (67%) 13 (48%) 10 (63%) 66 (53%)
3-4 84 (32%) 56 (28%) 20 (53%) 10 (23%) 8 (30%) 3 (19%) 41 (33%)
5e6 (least afﬂuent) 58 (22%) 39 (20%) 4 (11%) 4 (9%) 6 (22%) 3 (19%) 17 (14%)
Family history of PDb 12 (5%) 31 (16%) 2 (5%) 4 (9%) 1 (4%) 3 (19%) 10 (8%)
Current/ex-smokerc 159 (61%) 85 (43%) 23 (61%) 26 (63%) 17 (63%) 8 (50%) 74 (60%)
Vascular co-morbidityy 83 (32%) 62 (31%) 21 (55%) 16 (37%) 13 (48%) 9 (56%) 59 (47%)
Median duration symptoms
at diagnosis (months, IQR)d
e 14 (9, 24) 20 (6, 26.5) 12 (6, 24) 24 (8, 37) 13 (12, 24) 15 (7, 26)
Symptoms at diagnosis
Tremore 35 (14%) 171 (86%) 18 (47%) 30 (70%) 13 (48%) 6 (38%) 67 (54%)
Postural Instabilitye 62 (25%) 60 (30%) 27 (71%) 29 (67%) 25 (93%) 10 (63%) 91 (74%)
Prior fallsf 50 (20%) 76 (38%) 25 (66%) 32 (75%) 23 (85%) 9 (56%) 89 (72%)
Mean motor UPDRS (SD)g 3.5 (3.8) 24.9 (11.9) 31.4 (14.6) 32.8 (11.5) 35.6 (17.7) 30.9 (12.2) 32.8 (14.0)
HoehneYahr 3h n/a 51 (26%) 19 (50%) 25 (58%) 17 (65%) 10 (63%) 71 (57%)
GDS-15  5 (depressed)f 26 (11%) 61 (31%) 21 (55%) 16 (37%) 16 (59%) 8 (50%) 61 (49%)
MMSE<24i 2 (0.8%) 13 (7%) 11 (29%) 18 (62%) 5 (26%) 3 (23%) 37 (30%)
Schwab & England <80j 16 (6%) 51 (26%) 23 (60%) 28 (65%) 18 (67%) 7 (44%) 76 (61%)
Outcomes
Person-years of follow-up 1334 972 113 136 74 54 377
Total deaths 57 (22%) 73 (37%) 28 (74%) 35 (81%) 23 (85%) 10 (63%) 96 (77%)
Parkinsonian-related deaths* e 29 (40%) 13 (46%) 29 (83%) 19 (83%) 7 (70%) 68 (71%)
Median survival yrs (95% CI) # NE 7.8 (6.5, 9.4) 2.7 (1.7, 4.2) 3.3 (2.4, 4.1) 2.7 (1.1, 3.8) 3.3 (1.7, 6.9) 2.7 (2.3, 3.6)
Institutionalized at baseline 2 (0.8%) 3 (1.5%) 5 (13%) 8 (19%) 9 (33%) 2 (13%) 24 (19%)
Institutionalized during follow-up 11 (4%) 26 (13%) 8 (21%) 24 (56%) 9 (33%) 3 (19%) 44 (35%)
Median time to institution yrs (95% CI) # NE NE NE 1.8 (0.6, 2.6) 3.3 (1.0, 6.2) NE 3.1 (2.3, 4.3)
Dead at 3 yrs 28 (11%) 32 (16%) 21 (55%) 22 (51%) 16 (59%) 8 (50%) 67 (54%)
Dead or dependent at 3 yrs 46/216 (21%) 90/197 (46%) 32/34 (94%) 39/40 (98%) 26/27 (96%) 15/16 (94%) 112/117 (96%)
Figures given are numbers of patients and percentages unless otherwise stated.
PD- Parkinson's disease; DLB-dementia with Lewy bodies; MSA-multiple system atrophy; PSP-progressive supranuclear palsy; CBD-corticobasal degeneration; vascular-
vascular parkinsonism.
UPDRS-Uniﬁed Parkinson's Disease Rating Scale; GDS-15-Geriatric Depression Scale; MMSE-mini-mental state examination; IQReinterquartile range; CI e conﬁdence in-
terval; NE e not estimable.
z Small postcode measure of socioeconomic status based on proportions of overcrowding, male unemployment, low occupational social class and car ownership.
y Previous history stroke/transient ischemic attack or ischemic heart disease or peripheral vascular disease or diabetes at baseline.
* Parkinsonian-related death deﬁned as being due to end-stage disease or a complication of parkinsonism (e.g. a fall/fracture, immobility leading to pneumonia/venous
thromboembolism, aspiration pneumonia etc); percentage refers to % of deaths that were parkinsonism related.
# Median time calculated from Kaplan Meier estimates.
a Missing n ¼ 5 controls.
b Missing n ¼ 16 controls, n ¼ 2 vascular, n ¼ 1 PSP/CBD.
c Missing n ¼ 3 controls, n ¼ 1 PD, n ¼ 1 vascular, n ¼ 2 DLB, n ¼ 1 PSP/CBD.
d Missing n ¼ 2 vascular, n ¼ 1 MSA.
e Missing n ¼ 12 controls.
f Missing n ¼ 15 controls, n ¼ 1 vascular.
g Missing n ¼ 16 controls, n ¼ 1 PD.
h Missing n ¼ 1 PD, n ¼ 1 PSP/CBD.
i Missing n ¼ 16 controls, n ¼ 29 PD, n ¼ 12 vascular, n ¼ 14 DLB, n ¼ 8 PSP/CBD, n ¼ 3 MSA.
j Missing n ¼ 16 control, n ¼ 1 PD.
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tive and vascular parkinsonian disorders from incident cohorts and,
therefore, our data are important. These disorders were associated
with a much worse prognosis than controls and a poorer prognosis
than has generally been reported in the literature. Previous non-
incident cohorts have shown mean/median survival times from
diagnosis ranging from 1.8 to 9.7 years for PSP [18,19], 5.7e9 years
for MSA [20e22] and 4.4e7.3 years for DLB [23,24] with a HR for
survival in DLB versus a control population of 1.64 (95% CI
1.39e1.95) [25]. However, these cohorts were often relatively
young at diagnosis. The single incident cohort of PSP (n ¼ 16) and
MSA (n ¼ 9) showed median survival times of 5.3 and 8.5 yearsrespectively [26], longer than we found. Our median time to
institutionalization in DLB (1.8 years) was the same as one previous
study [27] but much shorter than another (6.1 years) [24].
The main strength of this study is its design, which follows best
practice for studying prognosis [3]: namely a population-based
incident cohort gathered using multiple methods of case-
ascertainment to maximize recruitment, which was then fol-
lowed up forwards in time to collect pre-speciﬁed information on a
number of different aspects of prognosis. There were few exclu-
sions due to lack of consent and few losses to follow-up, partly
because patients were seen at home when they were unable to
come to the clinic. There was also consistent application of
Fig. 2. Cumulative incidence curves for institutionalization by grouped diagnostic
category.
Fig. 1. Kaplan-Meier curves for all-cause mortality by grouped diagnostic category.
S. Fielding et al. / Parkinsonism and Related Disorders 32 (2016) 36e4140diagnostic criteria, reviewed by a single principal investigator and
conﬁrmed, where possible, by pathology at death. Therefore, our
data are likely to be less biased and more representative than much
of the previous published prognostic information on these
conditions.
There are also several limitations of our study. Although one of
the largest incidence studies of parkinsonism, it remains relatively
small and would beneﬁt from being combined with other similar
incidence studies with follow-up. Median follow-up is currently
only about ﬁve years but is continuing and so there will be further
data on longer term outcomes, especially for PD, in the future. As an
incidence study we had few patients with young-onset Parkinson's
disease (only nine patients were under 50 at diagnosis) and so the
ﬁndings cannot be generalized to young patients or predominantly
non-Caucasian populations. As with any clinical study of parkin-
sonism without 100% pathological conﬁrmation, there may be
some diagnostic inaccuracy but we applied robust diagnostic
criteria with yearly review of all available clinical data to minimize
errors.
Despite the fact that this was an incident cohort, the parkinso-
nian cohort appeared to have quite advanced disease at baseline.
We do not believe this reﬂects late diagnosis because median time
from symptom onset to diagnosis, as determined by patient recall
at their baseline interview, was only 15 months. Instead this may
reﬂect the older age of our cohort compared to other studies, whichTable 2
Adjusted risk ratios for different outcomes by diagnostic group.




HR 95% CI H
Control 255 (54) 1.00 e 253 (11) 1.
Parkinson's disease 198 (72) 2.49 (1.72, 3.58) * 195 (26) 3.
Atypical parkinsonismd 120 (92) 6.85 (4.78, 9.81) * 97 (42) 14
Vascular Parkinsonism 37 (27) 6.32 (3.91, 10.2)* 32 (8) 6.
Dementia with Lewy bodies 41 (33) 7.75 (4.88, 12.3)* 33 (22) 27
Parkinson Plus 42 (32) 6.58 (4.13.10.5) * 32 (12) 11
N ¼ total number of patients and controls included in analysis. Na ¼ number of people i
* p-value <0.001.
a Analysis adjusted for: age, sex, living alone, vascular co-morbidity, smoking, depriva
b Analysis with competing risk for death on those not institutionalized at baseline.
c Analysis only includes those independent at baseline, N ¼ 393 due to missing baseli
d Atypical parkinsonian patients analysed all together and repeated below subdividedin turn may reﬂect improved case-ascertainment in the elderly.
This highlights the importance of studying prognosis in represen-
tative rather than highly selected patient cohorts such as those
recruited from neurology clinics or trials [28]. Our controls were
not a random sample of the general population and had to have
capacity to provide informed consent and so may have been less
prone to dementia despite evidence showing that they were not
overly healthy [13].
This study fulﬁls criteria for a combined level 1 and 2 prognostic
study and has several implications for clinical practice, healthcare
planning and future research [1]. Firstly, atypical parkinsonism
syndromes are aggressive diseases with high levels of mortality,
dependency and institutionalization and require appropriate care
planning from an early stage. Secondly, despite available medical
treatments, PD also carries a high risk of death or dependency at
three years, especially in the elderly. Optimising therapy early with
levodopa may be the most appropriate strategy for many elderly
patients who may not survive long enough to develop motor
complications. Further research should concentrate on prognostic
modelling to try to predict outcomes or treatment responses in
individual patients, which may allow personalized approaches to
management [29]. Finally, it is important to include elderly
parkinsonian patients in future research to ensure that results can
be generalized to them and, given their worse prognoses, it maystitutionalizationa,b
¼ 545)
Na (ne) Dead or dependent at 3 years
and independent at baselinea,c (N ¼ 393)
R 95% CI OR 95% CI
00 e 202 (35) 1.00 e
98 (1.98, 8.00) * 147 (50) 3.87 (2.18, 6.86) *
.2 (7.17, 28.2) * 44 (39) 45.3 (15.3, 134.5)*
72 (2.47, 18.2)* 13 (11) 24.6 (4.90, 123.4)*
.7 (13.3, 57.6)* 13 (12) 73.1 (8.80, 606.7)*
.4 (4.70, 27.7) * 18 (16) 55.2 (9.80, 311.5) *
ncluded in analysis; Ne ¼ number of events; HR hazards ratio; OR odds ratio.
tion category.
ne Schwab & England scores.
into separate diagnostic groups.
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